Sarepta Therapeutics (NASDAQ:SRPT) announced Friday that the company and its partner Roche (OTCQX:RHHBY) expect to provide EU ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on ...

Orion Portfolio Solutions LLC lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 17.7% during the fourth quarter, according to the company in its most ...

LPL Financial LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 12.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 53,438 shares ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by investment analysts at HC Wainwright from a “sell” ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) fell in the premarket on Thursday following news regarding a clinical hold ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price reduced by Needham & Company LLC from $202.00 to $183.00 in a report published on Thursday,Benzinga reports. Needham & Company LLC ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an ...

Shares of some U.S. biotechnology companies including Moderna (MRNA) plunged on Monday after reports that the top vaccine ...